Cellectricon settles patent infringement litigation with Fluxion
Published on October 15, 2012 at 1:25 AM
Cellectricon AB and Fluxion Biosciences today announced that they have settled the patent infringement litigation that Cellectricon commenced against Fluxion in 2009.
Cellectricon and Fluxion have agreed to file a stipulation of dismissal with the United States District Court for the Northern District of California for all claims brought by Cellectricon against Fluxion for alleged infringement of Cellectricon's U.S. Patent Nos. 7,390,650, 7,470,518, and 7,563,614. Under the terms of the settlement, Fluxion and Cellectricon will cross-license patents related to microfluidic cellular analysis.
"We are very pleased to have achieved a successful conclusion to the litigation," said David A. Burns, Chief Executive Officer of Cellectricon. "Resolution of this lawsuit allows us to focus on providing innovative and enabling products and discovery services for drug discovery and life science research globally."
"Fluxion couldn't be more pleased with the settlement and the outcome of the litigation. We believe it is a win-win for both companies, and will benefit our customers as we can now focus all of our attention on developing and providing solutions that continue to deliver maximum benefit to them," said Jeff Jensen, CEO of Fluxion Biosciences.